Atezolizumab Plus Induction Chemotherapy Plus CT-radiotherapy. (APOLO)

Inclusion Criteria: * Male or female, aged ≥ 18 years old and ≤ 75 years. * ECOG Scale (Eastern Cooperative Oncology Group) of performance status of 0 or 1. * Histologically or cytologically confirmed, non-resectable Stage IIIA-IIIB NSCLC according to the 8th version of the International Association for the Study of Lung Cancer Staging Manual in Thoracic Oncology. * PET-CT (Positron Emission Tomography -Computed tomography) and brain computed tomography or Magnetic resonance imaging (MRI) at baseline to confirm the absence of distant disease. * Mediastinal involvement could be considered without histological confirmation when no margin can be distinguished in the lymph node mass. * No prior treatment with anti-neoplastic drugs or thoracic radiotherapy for Stage IIIA-IIIB NSCLC. * Patients who have received prior neo-adjuvant, adjuvant chemotherapy with curative intent for non-metastatic disease must have experienced a treatment-free interval of at least 6 months from enrollment since the last chemotherapy. * Presence of at least one measurable disease by CT-SCAN, as defined by RECIST v1.1. * Adequate hematologic and organ function defined by the following laboratory results obtained within 14 days prior to enrollment: * Neutrophils ≥ 1500 cells/μL without granulocyte colony-stimulating factor support. * Lymphocyte count ≥ 500/μL. * Platelet count ≥ 100,000/μL without transfusion. * Haemoglobin ≥ 10.0 g/dL. Patients may be transfused to meet this criterion. * INR or aPTT ≤ 1.…